title: Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies.
abstract: BACKGROUND
  The objective of this study was to develop pegylated poly lactide-co-glycolide acid (PLGA) immunonanocarriers for targeting delivery of docetaxel to human breast cancer cells.
  
  
  METHODS
  The polyethylene glycol (PEG) groups on the surface of the PLGA nanoparticles were functionalized using maleimide groups. Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) antigens of cancer cells, used as the targeting moiety, was attached to the maleimide groups on the surface of pegylated PLGA nanoparticles. Nanoparticles prepared by a nanoprecipitation method were characterized for their size, size distribution, surface charge, surface morphology, drug-loading, and in vitro drug release profile.
  
  
  RESULTS
  The average size of the trastuzumab-decorated nanoparticles was 254 ± 16.4 nm and their zeta potential was -11.5 ± 1.4 mV. The average size of the nontargeted PLGA nanoparticles was 183 ± 22 nm and their zeta potential was -2.6 ± 0.34 mV. The cellular uptake of nanoparticles was studied using both HER2-positive (SKBR3 and BT-474) and HER2-negative (Calu-6) cell lines.
  
  
  CONCLUSIONS
  The cytotoxicity of the immunonanocarriers against HER2-positive cell lines was significantly higher than that of nontargeted PLGA nanoparticles and free docetaxel.
authors.affiliation: Novel Drug Delivery Laboratory, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Mona Noori
authors.initials: MN
authors.lastname: Koopaei
authors.forename: Rassoul
authors.initials: R
authors.lastname: Dinarvand
authors.forename: Mohsen
authors.initials: M
authors.lastname: Amini
authors.forename: Hojatollah
authors.initials: H
authors.lastname: Rabbani
authors.forename: Shaghayegh
authors.initials: S
authors.lastname: Emami
authors.forename: Seyed Nasser
authors.initials: SN
authors.lastname: Ostad
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Atyabi
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D000077143:Docetaxel; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D008855:Microscopy, Electron, Scanning; D050997:Nanomedicine; D053758:Nanoparticles / Q000737:chemistry / Q000648:ultrastructure; D011092:Polyethylene Glycols; D011098:Polyglactin 910; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism*; D043823:Taxoids / Q000008:administration & dosage*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077143:Docetaxel; D004337:Drug Carriers; D011092:Polyethylene Glycols; D011098:Polyglactin 910; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab; C102418:poly(lactic-glycolic acid)-poly(ethyleneglycol) copolymer; C508053:ERBB2 protein, human